Table 1.
Comparison of the main characteristics of patients treated with remdesivir and patients who did not receive the drug.
| No Remdesivir (N = 221) |
Treated with Remdesivir (N = 173) |
p | |
|---|---|---|---|
| Demography and personal history | |||
| Age, years | 71 (61–80) | 60 (52–71) | <0.001 |
| Female sex, % | 42 | 39 | 0.641 |
| Chronic comorbidities, number | 3 (1–4) | 1 (0–3) | <0.001 |
| Chronic medications, number | 2 (1–5) | 1 (0–3) | <0.001 |
| Hypertension, % | 59 | 45 | 0.005 |
| Ischemic heart disease, % | 15 | 5 | 0.001 |
| Diabetes, % | 21 | 13 | 0.040 |
| Obesity, % | 13 | 17 | 0.194 |
| Dyslipidemia, % | 21 | 17 | 0.309 |
| Atrial Fibrillation, % | 16 | 6 | 0.001 |
| Chest CT presentation | |||
| Ground glass abnormalities on CT, % | 90 | 99 | <0.001 |
| Consolidations on CT, % | 69 | 71 | 0.782 |
| Visual score of pneumonia extension, % | 25 (15–45) | 20 (15–35) | 0.074 |
| Clinical presentation upon admission | |||
| PaO2/FiO2, mmHg | 276 (202–328) | 312 (264–352) | <0.001 |
| Duration of symptoms, days | 6 (2–10) | 7 (4–9) | 0.150 |
| Fever, % | 76 | 81 | 0.286 |
| Cough, % | 44 | 53 | 0.082 |
| Dyspnea,% | 58 | 43 | 0.003 |
| Diarrhoea, % | 17 | 16 | 0.790 |
| WHO COVID-19 Scale mild, % | 10 | 1 | <0.001 |
| WHO COVID-19 Scale moderate, % | 24 | 32 | 0.082 |
| WHO COVID-19 Scale severe, % | 27 | 42 | 0.002 |
| WHO COVID-19 Scale critical, % | 38 | 24 | 0.003 |
| Blood tests | |||
| Hemoglobin, g/dL | 13.8 (12.2–15.0) | 14.0 (12.9–15.0) | 0.055 |
| Platelet count, 1000/mm3 | 195 (146–266) | 187 (149–223) | 0.125 |
| White Blood Cell count, n/mm3 | 6980 (5113–8885) | 5500 (4060–7850) | <0.001 |
| Neutrophil count, n/mm3 | 5403 (3610–7392) | 4400 (2781–6243) | <0.001 |
| Creatinine, mg/dL | 0.9 (0.7–1.2) | 0.8 (0.7–1.0) | 0.004 |
| C-Reactive Protein, mg/L | 62 (29–107) | 46 (23–81) | 0.005 |
| Procalcitonin, ng/mL | 0.11 (0.06–0.39) | 0.07 (0.04–0.14) | <0.001 |
| Interleukin-6, pg/mL | 86 (29–182) | 79 (34–145) | 0.908 |
| D-dimer, ng/mL | 940 (532–1635) | 608 (420–906) | <0.001 |
| Other treatments administered | |||
| Enoxaparin, % | 95 | 97 | 0.401 |
| Corticosteroids,% | 90 | 99 | <0.001 |
| Antibiotics, % | 88 | 87 | 0.750 |
| Azithromycin, % | 29 | 47 | <0.001 |
Data are shown as median and interquartile range or percentages. Crude comparisons were made with Mann–Whitney test or chi-square test, as appropriate; p values < 0.05 are indicated in bold.